"muscle invasive bladder cancer" trang 2 - tải miễn phí từ tailieunhanh
Utility of SAM68 in the progression and prognosis for bladder cancer

Utility of SAM68 in the progression and prognosis for bladder cancer
8    52    1
High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer

High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer
10    79    1
Laminin-integrin a6b4 interaction activates notch signalling to facilitate bladder cancer development

Laminin-integrin a6b4 interaction activates notch signalling to facilitate bladder cancer development
11    25    1
Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer

Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer
6    65    0
Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: A Markov model

Low-dose Bacillus Calmette-Guerin versus full-dose for intermediate and high-risk of non-muscle invasive bladder cancer: A Markov model
8    39    1
B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscleinvasive bladder cancer patients

B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscleinvasive bladder cancer patients
9    73    1
Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: The PRE-PREVENCYS trial

Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: The PRE-PREVENCYS trial
11    44    1
Young age increases the risk of lymphnode metastasis in patients with muscleinvasive bladder urothelial carcinoma

Young age increases the risk of lymphnode metastasis in patients with muscleinvasive bladder urothelial carcinoma
6    34    1
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
11    34    1
Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models

Prediction of non-muscle invasive bladder cancer outcomes assessed by innovative multimarker prognostic models
9    54    1
Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer

Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer
11    56    1
Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: A systematic review

Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: A systematic review
15    56    1
Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscleinvasive bladder cancer (EFFORT-MIBC): A phase II prospective trial

Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscleinvasive bladder cancer (EFFORT-MIBC): A phase II prospective trial
7    56    1
Glycoprotein α-Subunit of Glucosidase II (GIIα) is a novel prognostic biomarker correlated with unfavorable outcome of urothelial carcinoma

Glycoprotein α-Subunit of Glucosidase II (GIIα) is a novel prognostic biomarker correlated with unfavorable outcome of urothelial carcinoma
16    17    1
Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification

Clinical outcomes of muscle invasive bladder Cancer according to the BASQ classification
8    54    0
An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: Influence of mouse strain, tumor cell count, dwell time and bladder pretreatment

An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: Influence of mouse strain, tumor cell count, dwell time and bladder pretreatment
12    56    1
A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging

A network meta-analysis of therapeutic outcomes after new image technology-assisted transurethral resection for non-muscle invasive bladder cancer: 5-aminolaevulinic acid fluorescence vs hexylaminolevulinate fluorescence vs narrow band imaging
10    51    1
Bipolar energy for transurethral resection of non muscle invasive bladder cancer - histopathological and predicting disease recurrence

Bipolar energy for transurethral resection of non muscle invasive bladder cancer - histopathological and predicting disease recurrence
6    17    1
PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: A single institution experience

PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: A single institution experience
6    1    1
Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS)

Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS)
1    90    0